β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of mAPK/ERK and PI3K/Akt/mtor signalling pathways

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2739-2744

  Zhan, Yun Hong ^a   Liu, Jing ^b   Qu, Xiu Juan ^b   Hou, Ke Zuo ^b   Wang, Ke Feng ^a   Liu, Yun Peng ^b   Wu, Bin ^a  

^a Department of Urology   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; mTOR; Renal cell carcinoma

Indexed keywords

EID: 84874062469     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2739     Document Type: Article

References (30)

1. Abou Youssif T, Fahmy MA, Koumakpayi IH, et al. (2011). The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer, 117, 290-300.
2. Amaravadi RK, Yu D, Lum JJ, et al. (2007). Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest, 117, 326-36.
3. Anandappa G, Hollingdale A, Eisen T (2010). Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag Res, 2, 61-70.
4. Borders EB, Bivona C, Medina PJ (2010). Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm, 67, 2095-106.
5. Bullock A, McDermott DF, Atkins MB (2010). Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res, 2, 123-32.
6. Chen W, Lu Y, Wu J, et al. (2011). Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol, 67, 799-808.
7. Escudier B, Eisen T, Stadler WM, et al. (2007). TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, 125-34.
8. Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010). mTOR regulation of autophagy. FEBS Lett, 584, 1287-95.
9. Li L, Gao Y, Zhang L, et al. (2008). Silibinin inhibits cell growth and induces apoptosis by caspase activation, downregulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett, 272, 61-9.
10. Lin F, Zhang PL, Yang XJ, et al. (2006). Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci, 36, 283-93.
11. Li QQ, Wang G, Huang F, Banda M, Reed E (2010). Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol, 62, 1018-27.
12. Li QQ, Wang G, Reed E, Huang L, Cuff CF (2010). Evaluation of Cisplatin in Combination with beta-Elemene as a Regimen for Prostate Cancer Chemotherapy. Basic Clin Pharmacol Toxicol, 107, 868-76.
13. Li QQ, Wang G, Zhang M, et al. (2009). beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep, 22, 161-70.
14. Li X, Fan Z (2010). The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1{alpha} and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res, 70, 5942-52.
15. Li X, Wang G, Zhao J, et al. (2005). Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci, 62, 894-904.
16. McDermott DF (2009). Immunotherapy of metastatic renal cell carcinoma. Cancer, 115, 2298-305.
17. Mizushima N (2008). Autophagy: process and function. Genes Dev, 21, 2861-73.
18. Motzer RJ, Hutson TE, Tomczak P, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24.
19. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP (2007). Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol, 177, 346-52.
20. Sasaki K, Tsuno NH, Sunami E, et al. (2010). Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer, 10, 370.
21. Takano Y, Iwata H, Yano Y, et al. (2010). Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochem Pharmacol, 80, 463-70.
22. Tan P, Zhong W, Cai W, et al. (2000). [Clinical study on treatment of 40 cases of malignant brain tumor by elemene emulsion injection]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 20, 645-8. [Article in Chinese]
23. Thorburn A (2008). Apoptosis and Autophagy: regulatory connections between two supposedly different processes. Apoptosis, 13, 1-9.
24. Wang G, Li X, Huang F, et al. (2005). Antitumor effect of betaelemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci, 62, 881-93.
25. Wang J, Zhang H, Sun Y, et al. (1996). Phase III clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi, 18, 464-7 (in Chinese).
26. Weston CR, Lambright DG, Davis RJ. (2002). Signal transduction: MAP kinase signaling specificity. Science, 296, 2345-7.
27. Yang Z, Klionsky DJ (2010). Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol, 22, 124-31.
28. Yao YQ, Ding X, Jia YC, et al. (2008). Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett, 264, 127-34.
29. Zhu K, Dunner K Jr, McConkey DJ. (2010). Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene, 29, 451-62.
30. Zhu T, Zhao Y, Zhang J, et al. (2011). ß-Elemene inhibits proliferation of human glioblastoma cells and causes cellcycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. Int J Oncol, 38, 419-26.